Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54


Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?

Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, Klocker H, Kay EW, Gallagher WM, Watson WR.

Prostate. 2013 May;73(7):743-53. doi: 10.1002/pros.22618. Epub 2013 Jan 28.


The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.

Lundon DJ, Boland A, Prencipe M, Hurley G, O'Neill A, Kay E, Aherne ST, Doolan P, Madden SF, Clynes M, Morrissey C, Fitzpatrick JM, Watson RW.

BMC Cancer. 2017 Mar 1;17(1):163. doi: 10.1186/s12885-017-3100-4.


YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.

Giménez-Bonafé P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC.

Prostate. 2004 May 15;59(3):337-49.


Relationship between serum response factor and androgen receptor in prostate cancer.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7.


Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC.

Cancer Res. 2004 Mar 15;64(6):2212-21.


Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.

Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME.

Cancer Res. 2003 Jul 1;63(13):3575-84.


Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.

Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, Lee AS, Cote RJ.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93.


Genomic strategy for targeting therapy in castration-resistant prostate cancer.

Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.

J Clin Oncol. 2009 Apr 20;27(12):2022-9. doi: 10.1200/JCO.2008.17.2882. Epub 2009 Mar 16.


Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.

Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.

Clin Cancer Res. 2005 Jul 1;11(13):4905-11.


Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance.

Srivastava SK, Bhardwaj A, Singh S, Arora S, McClellan S, Grizzle WE, Reed E, Singh AP.

Carcinogenesis. 2012 Jun;33(6):1149-57. doi: 10.1093/carcin/bgs134. Epub 2012 Mar 19.


Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.

Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS.

Prostate. 2007 Nov 1;67(15):1621-9.


The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.

O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2014 Feb;74(3):306-13. doi: 10.1002/pros.22752.


Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.

Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2507-11.


Identification of novel androgen receptor target genes in prostate cancer.

Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, Arasheben A, Tilley WD, Scher HI, Gerald WL, Buchanan G, Coetzee GA, Frenkel B.

Mol Cancer. 2007 Jun 6;6:39.


Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T.

J Pathol. 2012 Jul;227(3):336-45. doi: 10.1002/path.4027. Epub 2012 May 8.


Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.

Yano S, Matsuyama H, Hirata H, Inoue R, Matsumoto H, Ohmi C, Miura K, Shirai M, Iizuka N, Naito K.

Oncol Rep. 2006 Jun;15(6):1453-60.


Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.

Verone AR, Duncan K, Godoy A, Yadav N, Bakin A, Koochekpour S, Jin JP, Heemers HV.

Carcinogenesis. 2013 Aug;34(8):1737-46. doi: 10.1093/carcin/bgt126. Epub 2013 Apr 10.


Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.

Malinowska K, Cavarretta IT, Susani M, Wrulich OA, Uberall F, Kenner L, Culig Z.

Prostate. 2009 Jul 1;69(10):1109-18. doi: 10.1002/pros.20956.


Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.

Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi JP, Smit F, Verhaegh G, Schalken J, Perälä M, Iljin K, Kallioniemi O.

Prostate. 2012 May 15;72(7):789-802. doi: 10.1002/pros.21487. Epub 2011 Sep 14.


Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.

Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B.

Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591. Epub 2012 Oct 4.


Supplemental Content

Support Center